|1.||Psoriasis (Pustulosis Palmaris et Plantaris)
03/01/1984 - "Clinical trials with butantrone on psoriasis are justified."
01/01/1989 - "Short-contact therapy for psoriasis with 3.9% butantrone (10-butyryl dithranol)."
01/01/1986 - "An open clinical trial was carried out using butantrone ointment in the treatment of 10 patients with psoriasis in order to assess staining and irritation in relation to efficacy. "
01/01/1989 - "Previous studies have shown that when butantrone and dithranol were used in equimolar gradually increasing concentrations in short-contact therapy for psoriasis the efficacy of butantrone was somewhat lower compared to dithranol. "
01/01/1987 - "Comparison of dithranol and butantrone in short contact therapy of psoriasis."
01/01/1989 - "In general, the side-effects (erythema and staining) remained weaker on the butantrone-treated side than on the dithranol-treated side. "
01/01/1987 - "Both dithranol concentrations produced a markedly stronger increase of blood flow and erythema than any of the butantrone concentrations and a clear dose response when the concentration was raised from 0.1 to 0.5%. "
01/01/1987 - "When short contact treatment is used, erythema and staining with butantrone are weaker than with dithranol. "
01/01/1983 - "On the whole, erythema, contact temperature and superficial blood flow, as interdependent parameters of cutaneous inflammation, all showed a time-dependent statistically significant correlation to the dose of dithranol and 10-butyryl dithranol. "
01/01/1983 - "In equimolar concentrations corresponding to 0.05% dithranol, dithranol caused markedly more erythema and staining than 10-propionyl dithranol and 10-butyryl dithranol, whereas 10-butyryl dithranol irritated and stained less than 10-propionyl dithranol. "
04/01/1984 - "In the butantrone groups, there was only one single papilloma with the 1.5 mM concentration plus DMBA. "
10/01/1986 - "The first papillomas appeared 8-11 weeks after initiation and the incidences of papillomas at the end of the experiment were 85% (dithranol 3.5 mM), 16% (butantrone 30 mM), 36% (10-isobutyryl dithranol 30 mM) and 50% (10-valeryl dithranol 30 mM). "
04/01/1984 - "The tumor-producing activity of local applications of dithranol, 10-propionyl dithranol and butantrone was studied in 420 female white NMRI mice. "
10/01/1986 - "It is concluded that the tumor-producing and skin-irritating activity of dithranol is clearly greater than that of butantrone, 10-isobutyryl dithranol and 10-valeryl dithranol."
10/01/1986 - "The tumor-producing and skin-irritating activity of the antipsoriatic drug dithranol and its 10-acyl analogues butantrone (10-butyryl dithranol), 10-isobutyryl dithranol and 10-valeryl dithranol were studied in 650 SENCAR mice using a two-stage skin carcinogenesis assay. "